Longeveron Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.67 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.32M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Details
| Name | Longeveron Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 38 |
| Founded | 2014 |
| Ipo Date | 2021-02-12 |
| Ceo | Stephen Willard |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 10.00 |
| Isin | US54303L3024 |
| Cusip | 54303L302 |
| Cik | 1721484 |
| Sic | 2834 |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
Key executives
| Name | Title |
|---|---|
| Stephen H. Willard Esq. | Chief Executive Officer and Director |
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer and Executive Chairman |
| Paul T. Lehr J.D. | General Counsel and Secretary |
| Nirav Suresh Jhaveri C.F.A., M.B.A. | Chief Financial Officer and Principal Financial and Accounting Officer |
| Devin Blass | Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing and Controls |
Contact
| Address | Life Science & Technology Park, Suite 520, Miami, Florida 33136, United States |
| Phone | 844 470 2550 |
| Website | https://longeveron.com |